CTKB
HealthcareCytek Biosciences, Inc. · Medical - Devices · $520M
What is Cytek Biosciences, Inc.?
Cytek Biosciences is a small-cap cell analysis company focused on advancing biomedical research and clinical applications through full spectrum flow cytometry. Headquartered in Fremont, California, it serves pharmaceutical companies, academic research centers, and clinical research organizations globally.
Cytek Biosciences develops and sells spectrum flow cytometry instruments, reagents, and software that allow scientists to analyze individual cells with high precision. Its systems use fluorescence signatures from multiple lasers to distinguish tagged cells, enabling complex immunology and biomedical research workflows. The company generates revenue through instrument sales, consumable reagents, kits, and software licenses, with customers spanning drug discovery, academic science, and clinical research.
Cytek Biosciences went public in 2021 and is headquartered in Fremont, California.
- Aurora and Northern Lights spectrum flow cytometry systems
- Aurora Cell Sorter for advanced cell sorting applications
- cFluor reagents and 25-color immunoprofiling assay kits
- SpectroFlo software for workflow and data analysis
- Automated sample loader and micro-sampling systems
Is CTKB a Good Stock to Buy?
UQS Score rates CTKB as Poor overall, reflecting broad weakness across multiple fundamental pillars.
Among the five pillars, Risk stands out as the most neutral — suggesting the company does not carry extreme balance sheet or operational hazards relative to its size. This provides some floor for investors evaluating downside scenarios.
Quality, Moat, and Growth all register as Weak, indicating limited competitive differentiation, below-average financial returns, and constrained growth momentum at this stage. Valuation is rated Elevated, meaning the market price may not adequately reflect these fundamental challenges.
Pro members can view the complete pillar breakdown and underlying financial metrics to understand exactly where CTKB stands. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CTKB pay dividends?
No — Cytek Biosciences, Inc. does not currently pay a dividend.
Cytek Biosciences does not currently pay a dividend. As a small-cap company in a capital-intensive instrumentation and life sciences segment, available resources are directed toward product development, commercial expansion, and building out its distribution network rather than returning cash to shareholders.
When does CTKB report earnings?
Cytek Biosciences reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results reflect the challenges captured in its Weak Growth and Weak Quality pillar ratings — revenue expansion has been below what the market initially anticipated, and profitability metrics remain under pressure. Investors should monitor trends in instrument placements and recurring reagent revenue as indicators of commercial traction.
For the most recent quarter's results and guidance, visit Cytek Biosciences' official investor relations page.
CTKB Price History
-79.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Cytek Biosciences, Inc.?
Based on Cytek Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CTKB Long-term Outlook
The fundamental outlook for CTKB is cautious, shaped by Weak Growth and Weak Quality pillar ratings alongside an Elevated Valuation. Until the company demonstrates improving instrument adoption and a clearer path to profitability, the risk-reward profile remains challenging. The Neutral Risk rating does suggest the company is not in acute financial distress, which leaves room for a recovery narrative if commercial execution improves.
Growth drivers
- Expanding adoption of full spectrum flow cytometry in drug discovery and clinical research
- Recurring reagent and consumable revenue as the installed instrument base grows
- International distribution expansion across Europe and China
Key risks
- Elevated valuation relative to current financial performance creates limited margin of safety
- Weak moat exposes the company to competition from larger, better-resourced instrument makers
- Slow instrument placements could suppress recurring consumable revenue growth
CTKB vs Peers
Cytek Biosciences operates in a broader small-cap healthcare and medical device landscape alongside several peers tracked by UQS Score.
Tactile Systems focuses on at-home medical devices for chronic conditions, operating in a different clinical niche than Cytek's laboratory instrumentation business.
BrainsWay develops non-invasive brain stimulation therapies, making it a therapeutics-oriented peer rather than a research tools company.
SI-BONE specializes in minimally invasive surgical implants for the sacropelvic region, competing in surgical devices rather than cell analysis.
Frequently Asked Questions
What does Cytek Biosciences do?
Cytek Biosciences develops spectrum flow cytometry instruments, reagents, and software used by scientists to analyze individual cells. Its technology helps pharmaceutical companies, academic researchers, and clinical labs study immune cells and other biological targets with high precision.
Does CTKB pay dividends?
No, Cytek Biosciences does not pay a dividend. The company is in a growth and commercialization phase, directing capital toward expanding its product line and distribution rather than returning cash to shareholders.
When does CTKB report earnings?
Cytek Biosciences follows a standard quarterly earnings cadence for US-listed companies. For exact dates and the most recent results, check the investor relations section of the company's official website.
Is CTKB a good stock to buy?
UQS Score rates CTKB as Poor, with Weak readings across Quality, Moat, and Growth pillars and an Elevated Valuation. This profile suggests meaningful fundamental challenges. Pro members can access the full pillar breakdown to make a more informed assessment.
Is CTKB overvalued?
The UQS Valuation pillar for CTKB is rated Elevated, indicating the current market price may be high relative to the company's underlying financial performance. This is a notable concern given the Weak Quality and Growth ratings.
How does CTKB compare to its competitors?
CTKB operates in a specialized cell analysis niche. Peers tracked by UQS Score — including Tactile Systems, BrainsWay, and SI-BONE — serve different clinical and device markets. The UQS platform allows side-by-side pillar comparisons for a structured view of relative quality.
What is CTKB's market cap bracket?
Cytek Biosciences is classified as a small-cap company. This places it in a segment where liquidity, analyst coverage, and access to capital can be more limited than for mid- or large-cap peers in the healthcare sector.
Who founded Cytek Biosciences?
Founding details for Cytek Biosciences are widely available through public filings and the company's official website. The company became publicly listed in 2021 and is headquartered in Fremont, California.
Is CTKB a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates CTKB as Poor. Sustained improvement in the Quality, Moat, and Growth pillars would be necessary before the stock's long-term profile becomes more compelling. Monitoring quarterly progress is advisable.
What is the main competitive advantage of Cytek Biosciences?
Cytek's full spectrum profiling technology allows researchers to detect more fluorescent markers simultaneously than conventional flow cytometers. However, the UQS Moat pillar currently rates this advantage as Weak, suggesting it has not yet translated into durable competitive differentiation.
What sector does CTKB belong to?
Cytek Biosciences operates in the Healthcare sector, specifically within life science tools and instrumentation. Its products serve the research and clinical segments of the broader biomedical industry.
Is CTKB a growth stock or value stock?
Based on UQS pillar labels, CTKB carries a Weak Growth rating and an Elevated Valuation — an unfavorable combination that fits neither a classic growth nor a value profile. It may appeal to speculative investors betting on a commercial turnaround.
Unlock Full CTKB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare CTKB side-by-side with sector peers
- ✓Screen small-cap healthcare stocks by quality and risk
- ✓Track pillar changes as new earnings data arrives
Pro Analysis
CTKB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 19.2 | 9.6 | 21.0 | 16.9 | 54.5 | 0.0 | +2.1 |
| May 10, 2026 | 17.1 | 0.0 | 21.0 | 16.9 | 56.8 | 0.0 | +3.3 |
| May 9, 2026 | 13.8 | 0.0 | 21.0 | 0.0 | 56.8 | 0.0 | -0.4 |
| May 8, 2026 | 14.2 | 0.0 | 21.0 | 16.9 | 36.9 | 0.0 | -3.9 |
| Apr 26, 2026 | 18.1 | 9.6 | 21.0 | 16.9 | 47.1 | 0.0 | 0.0 |
| Apr 2, 2026 | 18.1 | 9.6 | 21.0 | 17.0 | 47.1 | 0.0 | — |
CTKB — Pillar Breakdown
Quality
— 9.6/100 (25%)Cytek Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 16.9/100 (20%)Cytek Biosciences, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 54.5/100 (15%)Cytek Biosciences, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Cytek Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 21/100 (25%)Cytek Biosciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CTKB.
Score Composition
Financial Data
More Stock Analysis
How is the CTKB UQS Score Calculated?
The UQS (Unified Quality Score) for Cytek Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Cytek Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Cytek Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.